| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| iboctadekin + rituximab | interleukin-18 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Lymphoma Follicular[MeSHID:D008224] Atrial Fibrillation[MeSHID:D001281] Non-Hodgkin[MeSHID:D008228] |
NA | phase 1 | unknown |
| iboctadekin + rituximab | leukocyte surface antigen leu-16 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Lymphoma Follicular[MeSHID:D008224] Atrial Fibrillation[MeSHID:D001281] Non-Hodgkin[MeSHID:D008228] |
NA | phase 1 | unknown |
| iboctadekin + rituximab | voltage-gated sodium channel alpha nav1.9 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Lymphoma Follicular[MeSHID:D008224] Atrial Fibrillation[MeSHID:D001281] Non-Hodgkin[MeSHID:D008228] |
NA | phase 1 | unknown |
| click here to return to the previous page | ||||||||